Clinical trial · Interventional
Contrast-enhanced Ultrasound With Perfluorobutane and Sulfur Hexafluoride for Hepatocellular Carcinoma
Perfluorobutane-enhanced Ultrasound as a Diagnostic Tool for Hepatocellular Carcinoma in Individuals With High Risk: Intraindividual Comparison With Sulfur Hexafluoride-enhanced Ultrasound
NCT04847726CI-TRIAL-00055413completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Intra-individual comparison of diagnostic performance of CEUS With perfluorobutane and sulfur hexafluoride for HCC in high-risk Individuals, and their role in the diagnostic algorithm of HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| contrast enhanced ultrasound | Diagnostic Test | — | UNRESOLVED |
| Dynamic CT | Diagnostic Test | — | UNRESOLVED |
| Liver MRI | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CEUS with perfluorobutane and sulfur hexafluoride
- description
- Contrast-enhanced ultrasound with perfluorobutane and sulfur hexafluoride for the hepatic lesion.
- interventionNames
- Diagnostic Test: contrast enhanced ultrasound
- Diagnostic Test: Dynamic CT
- Diagnostic Test: Liver MRI
Primary outcomes (1)
- measure
- Diagnostic accuracy for HCC: non-inferiority test
- timeFrame
- up to 3 months
- description
- The per-lesion diagnostic accuracy for HCC of CEUS with perfluorobutane and sulfur hexafluoride using the same diagnostic criteria (arterial phase hyperenehancement with mild and late (≥ 60 sec) washout).
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * high-risk for HCC (liver cirrhosis, chronic hepatitis B) * treatment-naive hepatic nodule (\>= 1cm) on preceding CT, MR or ultrasound Exclusion Criteria: * severe cardiopulmonary dysfunction * pregnancy * refusal to enroll study
References
Publications (1)
- DERIVEDKang HJ, Lee JM, Yoon JH, Yoo J, Choi Y, Joo I, Han JK. Sonazoid versus SonoVue(R) for Diagnosing Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound in At-Risk Individuals: A Prospective, Single-Center, Intraindividual, Noninferiority Study. Korean J Radiol. 2022 Nov;23(11):1067-1077. doi: 10.3348/kjr.2022.0388. Epub 2022 Sep 30. PMID 36196767